Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04550260 · ClinicalTrials.gov registry record · Phase 3

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

A Phase 3 study of Esophageal Squamous Cell Carcinoma, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
640
Enrollment target
20
Study locations

NCT04550260 is a Phase 3 study of Esophageal Squamous Cell Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 640 participants, above the 351-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04550260, a Phase 3 study of Esophageal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
640 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

Conditions Studied

Esophageal Squamous Cell Carcinoma

Interventions

  • DRUG Placebo
  • RADIATION Radiation
  • DRUG Durvalumab
  • DRUG cisplatin + fluorouracil
  • DRUG cisplatin + capecitabine

Study Locations (20)

Other

  • Research Site - Brussels
  • Research Site - Charleroi
  • Research Site - Liège
  • Research Site - Namur
  • Research Site - Barretos
  • Research Site - Fortaleza
  • Research Site - Porto Alegre
  • Research Site - Porto Alegre
  • Research Site - Rio de Janeiro
  • Research Site - São José do Rio Preto
  • Research Site - Vitória
  • Research Site - Anyang
  • Research Site - Beijing

Ontario

  • Research Site - Barrie
  • Research Site - Greater Sudbury

Georgia

  • Research Site - Atlanta

Kentucky

  • Research Site - Louisville

Texas

  • Research Site - Dallas

Virginia

  • Research Site - Fairfax

West Virginia

  • Research Site - Morgantown

Trial Details

FieldValue
Enrollment Target 640 participants
Start Date 2020-10-19
Est. Completion 2026-06-02
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04550260

The ClinicalTrials.gov registry entry for NCT04550260 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 351-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (82% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Esophageal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT04550260 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Ontario, Georgia.

Frequently Asked Questions

What is clinical trial NCT04550260 about?

NCT04550260 is a clinical study titled "Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC". This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

What is the current status of trial NCT04550260?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2020-10-19. Estimated completion is 2026-06-02.

What conditions does trial NCT04550260 study?

This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma.

What interventions are being tested in trial NCT04550260?

The interventions under investigation include: Placebo (DRUG), Radiation (RADIATION), Durvalumab (DRUG), cisplatin + fluorouracil (DRUG), cisplatin + capecitabine (DRUG).

Who is sponsoring clinical trial NCT04550260?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04550260 being conducted?

This trial has 20 study locations across Georgia, Kentucky, Texas, Virginia, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Esophageal Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Esophageal Squamous Cell Carcinoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.